Advertisement Pharmaceutical Business review - Page 97 of 5266 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 26, 2026

Daiichi Sankyo and Tempus AI collaborate on ADC clinical development

Daiichi Sankyo has entered a strategic collaboration with Tempus AI to expedite the clinical development and differentiation of an antibody drug conjugate (ADC) programme in the field of oncology.

The collaboration will deploy the AI models across Tempus’ oncology database. Credit: metamorworks / Shutterstock.com.